|
Demographic variables
| | |
|
Female gender, percentage
|
91
| |
|
Caucasian race, percentage
|
77
| |
|
Age, years
|
41 ± 13
| |
|
Comorbidity
| | |
|
Diabetes mellitus, percentage
|
4.9
| |
|
Clinical and laboratory variables
| | |
|
Disease duration, years
|
6.8 ± 4
| |
|
SLEDAI
|
4.7 ± 4
| |
|
ECLAM
|
3.1 ± 1.6
| |
|
SLICC/ACR damage index
|
1.4 ± 1.9
| |
|
Previous biopsy proven lupus nephritis, percentage
|
31.1
| |
|
Creatinine clearance <70 ml/minute, percentage
|
18
| |
|
Proteinuria, percentage
|
13.6
| |
|
Leucopoenia ever, percentage
|
36.9
| |
|
Functional MBL serum level, median (range) μg/ml
|
1.4 (0.04–7.60)
|
1.1 (0.0–11.2)
|
|
Functional MBL serum level <0.05 μg/ml, percentage
|
13
|
14
|
|
MBL-induced C4 deposition on mannan, median (range) percentage
|
71 (1.1–399)
|
114 (3–494)
|
|
MBL-induced C4 deposition on mannan <10%, percentage
|
21
|
16
|
|
Functional activity of the MBL pathway, median (range) percentage
|
16 (0.1–119)
|
56 (0–133)
|
|
Functional activity of the MBL pathway <10%, percentage
|
43
|
28
|
|
C3 levels in serum, median (range) g/l
|
0.86 (0.06–1.70)
|
(0.88–2.01)
|
|
C4 levels in serum, median (range) g/l
|
0.13 (0.07–0.35)
|
0.21 (0.11–0.61)
|
|
Therapy variables
| | |
|
Oral corticosteroids
| | |
|
Ever user, percentage
|
81
| |
|
Current user, percentage
|
52
| |
|
Duration of corticosteroid use in ever users, months
|
63 ± 70
| |
|
Actual prednisone dose if >0 mg/day, mg
|
13 ± 12
| |
|
Intravenous methylprednisolone use ever, percentage
|
15
| |
|
Hydroxychloroquine use ever, percentage
|
87
| |
|
Azathioprine use ever, percentage
|
37
| |
|
Methotrexate use ever, percentage
|
14
| |
|
Cyclophosphamide (oral and/or intravenous) use ever, percentage
|
13
| |
